Insulet Corporation Q2 FY26 Results — Earnings Call Analysis
Published 30 May 2026 | Health Care Equipment and Supplies | Market Cap: ₹9.9K Cr
- Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24%. - Adjusted EPS expected to increase by more than 25% in 2026.
From Insulet Corporation's Q2 FY26 earnings-call transcript · updated 30 May 2026.
Price
₹142.65
Market Cap
₹9.9K Cr
P/E Ratio
35.9
Revenue Rank
Margin Rank
How does Insulet Corporation rank in Health Care Equipment and Supplies?
Compare Insulet Corporation against every Health Care Equipment and Supplies company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24%.
- →U.S. Omnipod revenue expected to grow 20%-22% in 2026, driven by new customer starts, positive pricing, and sustained utilization.
- →International Omnipod revenue forecast at 26%-28% growth in 2026, supported by new customer sites, price/mix benefits from DASH to Omnipod 5 transition, and geographic expansion (e.g., Spain launch H2 2026).
- →2027 growth to be supported by the launch of Omnipod 6 and full benefit of salesforce expansion.
- →Algorithm improvements and Libre 3 Plus sensor integration expected to expand total addressable market (e.g., ~450,000 additional users in U.S.).
- →Continued commercial investments, salesforce upskilling, prescriber education, and market access initiatives aimed at sustaining high growth rates and category expansion.
- →Long-term confidence in sustaining approximately 20% growth driven by innovation and commercial catalysts.
📈 Profitability & Margins
Rank 2- →Adjusted EPS expected to increase by more than 25% in 2026.
- →Operating margin anticipated to expand by approximately 100 basis points in 2026, driven by strong top-line growth, gross margin expansion, and disciplined spending.
- →First quarter 2026 adjusted operating margin expanded 110 basis points to 17.5%.
- →Free cash flow expected to be approximately flat to 2025 levels, supported by growth and margin expansion, partially offset by increased capital expenditures.
- →Continued investments planned in R&D and sales & marketing to support innovation and commercial expansion.
- →Confidence in sustaining 20% total Omnipod revenue growth over long-run plan, driven by product innovations (Omnipod 6, Libre 3 Plus integration, algorithm enhancements) and sales force expansion.
- →Foreign currency expected to provide a favorable impact (~100 basis points) on full-year revenue growth in 2026.
🏗️ Capital Expenditure Plans
Yes- →The company is ramping up capital expenditures to support continued global manufacturing expansion plans.
- →A water-type manufacturing building is expected to be ready by year-end and go live in 2029.
- →Investments in R&D are being increased to support the innovation roadmap and key clinical development programs, including Omnipod 6 and fully closed loop for type 2 diabetes.
- →The ramp-up in sales and marketing investments is planned to expand the sales force and prepare for upcoming product launches such as Libre 3 Plus integration and algorithm enhancements.
- →These strategic investments aim to enable continued growth, broaden healthcare professional coverage, increase new customer starts, and support global scale.
💰 Fundraising & Capital Structure
No information- →No mention of any current or planned new fundraising through debt or equity in the provided pages.
- →The company expects 2026 net interest expense to be approximately $40 million, up about $15 million primarily due to lower interest income, implying use of existing debt.
- →Focus is on growing revenue and operating margin expansion to support earnings and free cash flow.
- →Capital expenditures are ramping up to support global manufacturing expansion but are funded through operations.
- →No explicit indication of issuing new debt or equity to raise capital during this period.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Health Care Equipment and Supplies this season
- Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
- Zimmer Biomet Holdings, Inc. (Q2 FY26)
Zimmer Biomet Holdings, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $16,023, P/E 21.9. AI-powered earnings insights.
Frequently Asked Questions
What were Insulet Corporation Q2 FY26 results?
- Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24%. - Adjusted EPS expected to increase by more than 25% in 2026.
What is Insulet Corporation share price analysis?
Insulet Corporation currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 35.9 with a market cap of $9,881. Investors should review the full earnings analysis for detailed insights.
Is Insulet Corporation planning capital expenditure?
- The company is ramping up capital expenditures to support continued global manufacturing expansion plans.
Keep Insulet Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.